参考文献

---

［1］Abernethy DR, Flockhart DA. Molecular basis of Cardiovascular drug metabolism. Implication for predicting clinically important drug interaction. Circulation,2000,101:1749

［2］Bartalena L,Brogioni S,Grasso L,et al. Treatment of amiodarone induced thyrotoxicosis, a difficult challenge: Results of a prospective Study. J Clin Endocrinol Metab,1996,81:29～30

［3］Bogazzi F, Bartalena L, Brogioni S, et al. Color flow Doppler Sonography rapidly differentiales type Ⅰ and type Ⅱ amiodarone-induced thyrotoxicosis. Thyroid, 1997, 7: 541

［4］Buxton AE, Lee KL, Fisher JD, et al. For the Multicenter unsustained Tachycardia Trial Investigators: A randomized study of the prevention of sudden death in patients with Coronary artery disease. N Engl J Med, 1999,341: 1882～1890

［5］Clark RF, Barton ED. Pitfolls in the administration of digoxin-specific Fab fragments. J Emer Med,1994,12:333

［6］Dr rote V, Carlsson B, Haggblad J, et al. Amiodarone is a dose-dependent noncompetitive and Competitive inhibition of T₃ binding to thyroid hormone receptor subtype beta l, whereas disopyramide, lidocain, propafenone, metoprolol, desotalol,and verapamil have no inhibitory effect. J Cardiovasc pharmacol,1995,26:222

［7］Fromm MF, Kim RB, Stein M, et al. Inhibition of P-glycoprotein mediated drug transport. A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation, 1999,99:552

［8］Hazai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med,1997,126:63

［9］Kaye DM, Dart AM, Jennings GL,et al. Antiadrenergic effect of chronic amiodarone therapy in Human heart failure. Am coll Cardiol,1999,33:1553～1559

［10］Kowey PR, Vanderlugt J, Luderer JR. Safety and risk/benefit of ibutilide for acute Conversion of atrial fibrillation/flutter. Am J Cardiol,1996,78:46～52

［11］Kelly RA, Smith TW. Antibody therapies for drug overdose in Austen K, Burakoff SJ, Rosen FS, Strom TR (eds): Therapeutic Immunology. Blackwell, Cambridge, MA,1995

［12］Lervasi G, Clerico A, Bonini R, et al. Acute effects of amiodarone administration on thyroid function in patients with Cardiac arrhythmia. J Clin Endocrinol Metab,1997,82:275

［13］Moss AJ, Hall WJ, Cannom DS, et al. For the Multicenter Automatic Defibrillator implantation Trial Investigators: Improved survival with an implanted defibrillator in patients with Coronary disease at high risk for Ventricular arrhythmia. N Engl J Med,1996,335:1933～1940

［14］Maisal WH, Kantz KM, Reimold SC,et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med,1997,127: 281～284

［15］Newman CM, Price A, Davies DW,et al. Amiodarone and the throid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart,1998,79:121～127

［16］Naccarelli G, Wollrette DL, Luck JC. Proarrthythmia. Med Clin Nor Amer,2001,85(2):503～526

［17］Opie LH. Adverse Cardiovascular drug reaction. Curr Probl Cardiol, 2000, 25: 621

［18］Toft AD, Boon NA. Thyroid disease and the heart. Heart, 2000,84:455～460

［19］Weirsinga WM. Amiodarone and thyroid in. Weetman AP. Grossman A. Pharmacotherapeutics of the thyroid gland. Berlin:Springer,1997,225～87